Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Wu, Z. [1 ]
Pan, H. [2 ]
Ye, M. [3 ]
Chen, L. [4 ]
Qian, W. [4 ]
Zhang, J. [4 ]
机构：
[1] Univ Minnesota, Sci & Engn, Minneapolis, MN 55455 USA
[2] Guangzhou Med Univ, Affiliated Hosp 1, Translat Med, Guangzhou, Guangdong, Peoples R China
[3] Guangzhou Chest Hosp, Internal Med, Guangzhou, Guangdong, Peoples R China
[4] Guangzhou Med Univ, Affiliated Hosp 1, Internal Med, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Apatinib; advance NSCLC; VEGFR-2; inhibitors;
D O I：
10.1016/j.jtho.2018.08.1186
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-131
引用
收藏
页码：S715 / S715
页数：1
相关论文
共 50 条
  • [41] Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
    Besse, Benjamin
    Planchard, David
    Veillard, Anne-Sophie
    Taillade, Laurent
    Khayat, David
    Ducourtieux, Muriel
    Pignon, Jean-Pierre
    Lumbroso, Jean
    Lafontaine, Carole
    Mathiot, Claire
    Soria, Jean-Charles
    LUNG CANCER, 2012, 76 (01) : 78 - 83
  • [42] Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
    Li, Fang
    Zhu, Tengjiao
    Cao, Baoshan
    Wang, Jiadong
    Liang, Li
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 184 - 192
  • [43] Combination of Apatinib and Salidroside Inhibits the Progression of Non-Small Cell Lung Cancer through MAPK/ERK/VEGF Signaling Axis
    Li, Jia-lu
    Xi, Ju-qun
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (04) : 3111 - 3121
  • [44] Continuous Administration of Low-Dose Apatinib Combined With WBRT for Non-Small Cell Lung Cancer With Symptomatic Brain Metastases
    Jia, Y.
    Ren, Y.
    Wang, S.
    Li, T.
    Lei, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S680 - S680
  • [45] Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer A case report
    Liu, Jin
    Zheng, Yulong
    Xu, Nong
    MEDICINE, 2019, 98 (05)
  • [46] Apatinib plus icotinib in treating advanced non small cell lung cancer after icotinib treatment failure: a retrospective study
    Xu, Jianping
    Liu, Xiaoyan
    Yang, Sheng
    Zhang, Xiangru
    Shi, Yuankai
    ONCOTARGETS AND THERAPY, 2017, 10 : 4989 - 4995
  • [47] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [48] A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy
    Dong, Shuang
    Ou, Wuling
    Zhong, Yi
    Zhu, Xianmin
    Cai, Qian
    Zhang, Jing
    Ran, Fengming
    Qian, Yu
    Wang, Jun
    Hu, Sheng
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [49] MYC and non-small cell lung cancer: A comprehensive review
    Kenzerki, Maryam Eftekhari
    Ahmadi, Mohsen
    Mousavi, Pegah
    Ghafouri-Fard, Soudeh
    HUMAN GENE, 2023, 37
  • [50] Lorlatinib for the treatment of patients with non-small cell lung cancer
    Akamine, T.
    Toyokawa, G.
    Tagawa, T.
    Yamazaki, K.
    Seto, T.
    Takeo, S.
    Mori, M.
    DRUGS OF TODAY, 2019, 55 (02) : 107 - 116
12345